GeneBioTech Co Ltd
KOSDAQ:086060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GeneBioTech Co Ltd
Operating Income
GeneBioTech Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GeneBioTech Co Ltd
KOSDAQ:086060
|
Operating Income
₩4.3B
|
CAGR 3-Years
54%
|
CAGR 5-Years
48%
|
CAGR 10-Years
17%
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩1.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Operating Income
-₩123.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Income
-₩36.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
₩106.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
300%
|
CAGR 10-Years
97%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩40.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
GeneBioTech Co Ltd
Glance View
Gene Bio Tech Co., Ltd. engages in the manufacture of fermented biomass. The company is headquartered in Gongju, Chungcheongnam-Do. The company went IPO on 2006-04-28. is a company mainly engaged in the production and sale of feed additives and animal drugs. Along with subsidiaries, the Company operates its business through two segments. The Additive segment is involved in the manufacturing and sale of fermented products and bio starches. The Animal Drug segment is involved in the manufacturing and sale of livestock and fish medicine. The main products include vitamins, minerals, antibiotics, nutrients, immune stimulators, digestion and absorption promoters, among others. The firm distributes its products within the domestic market and to overseas markets, including America.
See Also
What is GeneBioTech Co Ltd's Operating Income?
Operating Income
4.3B
KRW
Based on the financial report for Sep 30, 2025, GeneBioTech Co Ltd's Operating Income amounts to 4.3B KRW.
What is GeneBioTech Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
17%
Over the last year, the Operating Income growth was 35%. The average annual Operating Income growth rates for GeneBioTech Co Ltd have been 54% over the past three years , 48% over the past five years , and 17% over the past ten years .
